Heart Heath Study
Have you experienced a heart attack or unstable angina?
You may be eligible to take part in new heart disease research investigating the safety of an investigational medication, UDP-003, and it's potential to reduce plaque in the arteries in people who have experienced Acute Coronary Syndrome.
Critical Eligibility Criteria:
To take part in this study, you will need to meet all the following:
- Aged 40-79 (inclusive)
- Diagnosis of Acute Coronary Syndrome and be at least 12 months post cardiac event
- BMI between 18 and 34
- Be on a stable medication regime if applicable, with no planned changes during the study period.
Commitment:
Each participant's time on the study is expected to be up to 28 weeks in duration. This is inclusive of approximately 9 visits to the study site.
Locations:
South Australia
If you take part in this research study, there will be:
Reimbursement of costs
For out-of-pocket expenses, such as travel and parking.
Convenience
There are no overnight stays
Free study-related medical care
Be among the first to access potential new research treatments before they are widely available.
Expert medical monitoring
Receive top-tier medical care and monitoring from experienced healthcare professionals.
Contribution to medical research
Help investigate a potential new treatment that could improve the lives of individuals with heart conditions
Register your interest now
or scroll down to read the study FAQs
Study Guide
01
Who can take part in this study?
-
To take part in this study, you will need to meet all the following (other criteria apply):
- Aged 40-79 (inclusive)
- Diagnosis of Acute Coronary Syndrome and be at least 12 months post cardiac event
- BMI between 18 and 34
- Be on a stable medication regime if applicable, with no planned changes during the study period.
02
Who is unable to take part in this study?
+
Unfortunately, if any of the following apply to you, this study is not the right fit for you:
- Currently pregnant, planning to become pregnant or breast feeding
- Participation in a clinical trial within the past 3 months
- History of a cancer diagnosis within the past 5 years (excluding non Melanoma Skin Cancer)
- Cardiac related hospitalisation or cardiac intervention requiring hospitalisation within the past 12 months
- History of or planned coronary artery bypass grafting
Please note, additional eligibility criteria apply.
03
What does the study involve for participants?
+
If you are deemed eligible for the study, your participation is expected to last approximately 28 weeks, and you will be required to attend the study site up to 9 times. This includes:
- 1 initial screening visit
- 8 follow up visits
Participation in this research is voluntary, and you may withdraw from the study at any time.
04
What is the purpose of this study?
+
This study aims to evaluate the safety and efficacy of an investigational drug that is aimed at reducing the plaque burden within the arteries.
05
What is Acute Coronary Syndrome?
+
Acute Coronary Syndrome is the term given to heart conditions in which supply of blood to the heart is affected causing chest pain/heart events relative to potential blockage*.
06
Why is this study important?
+
The condition that is at risk of becoming Acute Coronary Syndrome is atherosclerosis which is one of the leading causes of mortality across the word. This condition occurs when there is a build up of plaque in the arteries and can lead to heart conditions associated with blockages.
07
Who is sponsoring this study?
+
This study is being sponsored by Cyclarity Therapeutics located in Novato, California.
08
Where is my nearest study site?
+
Here is a list of all of the sites who are currently recruiting for this study:
-
CMAX Clinical Research, Adelaide, South Australia
09
What if I have other questions about the study?
+
We are here for you! Head to our Evrima Help Centre and search for answers relating to clinical trials, study information and managing your Evrilink account
This study has been approved by an independent Human Research Ethics Committee
Help make medical research breakthroughs happen.
Need help with clinical trial information?
Search our Evrima help Centre for answers related to information about our active studies, information about managing your Evrilink account, and general clinical trial knowledge!
Read our FAQs